| Jun 4 |
Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
|
| Jun 3 |
Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20
|
| May 29 |
Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting
|
| May 22 |
Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
|
| Apr 11 |
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
|
| Mar 28 |
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
|
| Mar 18 |
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
|
| Mar 13 |
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
|
| Mar 4 |
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
|
| Feb 29 |
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
